Cidara治療 CDTX 深 滬
等待開盤 10-04 09:30:00 美东时间
101.99
+3.490
+3.54%
華盛通- 最 高106.63
- 今 開99.81
- 成交量 142.35万股
- 最 低 98.91
- 昨 收 98.50
- 總市值 13.23亿
- 52周最高 106.63
- 市盈率 靜 --
- 換手率 10.98%
- 52周最低 10.14
- 委 比 33.33%
- 總股本 1296.98万
- 歷史最高 382.60
- 量 比 0.91
- 振 幅 7.84%
- 歷史最低 8.00
- 每 手 1
- 風險率 2.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cidara Shares Are Trading Higher Friday: What's Going On?
Cidara shares are trading higher Friday after the company secured $339 million in BARDA funding to advance its CD388 pandemic influenza therapeutic and onshore its manufacturing.
今天 00:53
Cidara Secures Up To $339M BARDA Award To Advance CD388 Pandemic Influenza Therapeutic and U.S. Manufacturing
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an award valued up to
10-03 04:06
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic
Cidara Therapeutics received a $339M award from BARDA to support CD388 manufacturing in the U.S. and further development of this investigational drug for universal influenza prevention. The funding will enable clinical trials, production scaling, and preparedness for a potential influenza pandemic, especially benefiting immune-compromised individuals and the elderly. CD388, a long-acting drug-Fc conjugate, does not rely on immune response, offeri...
10-02 20:01
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
美股周涨跌榜 | 股价狂飙近300%！uniQure在研创新药获突破进展；特朗普政府寻求入股Lithium
股价周内狂飙近300%！uniQure在研创新药获重大进展；特朗普政府"盯上"锂矿巨头股权，Lithium Americas周内大涨95%>>
09-28 10:10
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations
Cidara Therapeutics has initiated a Phase 3 trial for CD388, a non-vaccine preventive for seasonal influenza, targeting high-risk populations including adults over 65 and those with comorbidities or immune compromise. The trial, named ANCHOR, aims to enroll 6,000 participants globally and assess the safety and efficacy of a single 450-mg subcutaneous dose. Mid-sign analysis post-Northern Hemisphere flu season will guide further enrollment. CD388 ...
09-25 20:01
美股牛股 | 特朗普政府拟购10%股权！锂矿股Lithium上演翻倍行情；创新药公司uniQure单日暴涨247%
特朗普政府拟购10%股权！锂矿股Lithium股价上演翻倍行情；创新药公司uniQure单日暴涨247%，核心在研药获关键进展，拟增发募资2亿美元>>
09-25 16:47
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
Cidara Therapeutics更新了CD388的第三阶段临床试验计划，根据FDA的反馈加速了时间表，提前在2025年秋季启动。试验将扩展至65岁以上的成年人，并包括有高度风险共病和免疫力低下的受试者，预期能覆盖超过10000万潜在参与者，以更好地满足流感预防的需求。
09-24 11:00
